The world’s first Nectin-4-targeting ADC to enter Phase III development in triple-negative breast cancer is now being ...
While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results